Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03103893 · ClinicalTrials.gov registry record · Phase 1
Novel Compositions for Treating or Preventing Dermal Disorders
A Phase 1 study of Dermal Atrophy, sponsored by Drexel University.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT03103893: Completed Phase 1 study of Dermal Atrophy, sponsored by Drexel University.
NCT03103893 is a Phase 1 study of Dermal Atrophy that has completed, run by Drexel University. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03103893, a Phase 1 study of Dermal Atrophy, has completed, sponsored by Drexel University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial examines the impact of a topical formulation of rapamycin on dermal thickness and senescence.
Primary Outcome
dermal thickness as assessed by direct measurement
Conditions Studied
Interventions
- DRUG Rapamycin
Study Locations (1)
Pennsylvania
- Drexel Dermatology - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 1 |
What the finished NCT03103893 record still lists
NCT03103893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Dermal Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Rapamycin is the first listed.
NCT03103893 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03103893 about?
NCT03103893 is a clinical study titled "Novel Compositions for Treating or Preventing Dermal Disorders". This trial examines the impact of a topical formulation of rapamycin on dermal thickness and senescence.
What is the current status of trial NCT03103893?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2017-09-25. Estimated completion is 2017-11-30.
What conditions does trial NCT03103893 study?
This clinical trial studies the following conditions: Dermal Atrophy.
What interventions are being tested in trial NCT03103893?
The interventions under investigation include: Rapamycin (DRUG).
Who is sponsoring clinical trial NCT03103893?
This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03103893 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03103893's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI